ACADIA Pharmaceuticals Inc to Announce Phase 3 Development Candidate ACP-101 Call Transcript
Good day, ladies and gentlemen, and welcome to ACADIA Pharmaceuticals conference call. My name is Jonathan, and I will be your coordinator for today. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of today's call. I would now like to turn the presentation over to Mark Johnson, Vice President of Investor Relations at ACADIA. Please proceed.
Thank you. Good afternoon, and thank you for joining us on today's call to discuss ACADIA's ACP-101 program for the treatment of Prader-Willi syndrome. Joining me on the call today from ACADIA are Steve Davis, our President and Chief Executive Officer, who will provide some opening remarks on our ACP-101 program in Prader-Willi syndrome and our Levo Therapeutics acquisition before turning it over to Kathie Bishop, our Chief Scientific Officer and Head of Rare Disease, will provide a more complete overview on the syndrome, ACP-101 and our Phase III program. Steve
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
